Epstein-Barr virus latent membrane protein 2-derived peptide–major histocompatibility complex (EBV LMP2-pMHC) (EBV LMP2-pMHC)

The Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2)-derived peptide–major histocompatibility complex (MHC) is a critical immunological target for treating EBV-associated malignancies. LMP2, particularly the LMP2A isoform, is a viral protein expressed during the latency II and III stages of the EBV life cycle, which are associated with diseases such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorder (PTLD) (Source: UniProt P13285). Intracellular LMP2 is processed into short peptides that are presented on the cell surface by MHC Class I molecules, most commonly HLA-A*02:01, allowing the immune system to identify infected or transformed cells (Source: PubMed 25631053). Because LMP2 is a non-self viral protein, these complexes serve as highly specific targets for adoptive T-cell therapies, including TCR-engineered T cells (TCR-T) and EBV-specific cytotoxic T lymphocytes like Tabelecleucel (Source: Atara Biotherapeutics). Therapeutic intervention involves the recognition of these pMHC complexes by specific T-cell receptors, leading to the targeted destruction of tumor cells while minimizing damage to healthy, non-infected tissues. However, challenges such as tumor-mediated HLA downregulation and the potential for off-target cross-reactivity with similar human peptides remain key considerations in drug development (Source: PubMed 30104633).

Other names

LMP2-HLA complexEBV LMP2 peptide-HLA complexLMP2-MHC class I complexLatent membrane protein 2-MHC complexLMP2-pMHCLMP2-HLA-A*02:01 complex

T-cell receptor (TCR) mediated recognition of the specific viral peptide-MHC complex, triggering cytotoxic T-lymphocyte (CTL) activation and subsequent apoptosis of the target cell.